{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:02:48Z","timestamp":1775581368132,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000374","name":"British Medical Association","doi-asserted-by":"publisher","award":["MTemple2016"],"award-info":[{"award-number":["MTemple2016"]}],"id":[{"id":"10.13039\/501100000374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_16014"],"award-info":[{"award-number":["MC_PC_16014"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["G0901310"],"award-info":[{"award-number":["G0901310"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Marie-Sk\u0142odowska Curie Individual Fellow"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1038\/s41397-019-0142-9","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:05:54Z","timestamp":1580774754000},"page":"629-637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"20","author":[{"given":"Maria Stella","family":"Calafato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3428-5070","authenticated-orcid":false,"given":"Isabelle","family":"Austin-Zimmerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan H.","family":"Thygesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mani","family":"Sairam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Metastasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Marston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-8885","authenticated-orcid":false,"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Harju-Sepp\u00e4nen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haritz","family":"Irizar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirini","family":"Zartaloudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1369-5983","authenticated-orcid":false,"given":"Elvira","family":"Bramon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"key":"142_CR1","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40263-013-0114-6","volume":"27","author":"WK Kennedy","year":"2013","unstructured":"Kennedy WK, Jann MW, Kutscher EC. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs. 2013;27:1021\u201348.","journal-title":"CNS Drugs."},{"key":"142_CR2","unstructured":"NICE. Psychosis and schizophrenia in adults: treatment and management: updated edition 2014. NICE. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25340235."},{"key":"142_CR3","unstructured":"NICE. Bipolar disorder: assessment and management. NICE guideline. 2014;1\u201358. https:\/\/www.nice.org.uk\/guidance\/cg185."},{"key":"142_CR4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0165-6147(00)01717-X","volume":"22","author":"M Pirmohamed","year":"2001","unstructured":"Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharm Sci. 2001;22:298\u2013305.","journal-title":"Trends Pharm Sci"},{"key":"142_CR5","doi-asserted-by":"crossref","unstructured":"Xu Q, Wu X, Xiong Y, Xing Q, He L, Qin S. Pharmacogenomics can improve antipsychotic treatment in schizophrenia. Front Med. 2013;7:1\u201311.","DOI":"10.1007\/s11684-013-0249-3"},{"key":"142_CR6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11920-018-0886-y","volume":"20","author":"J-P Zhang","year":"2018","unstructured":"Zhang J-P, Malhotra AK. Recent progress in pharmacogenomics of antipsychotic drug response. Curr Psychiatry Rep. 2018;20:24. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29589131%0A, http:\/\/link.springer.com\/10.1007\/s11920-018-0886-y.","journal-title":"Curr Psychiatry Rep"},{"key":"142_CR7","unstructured":"Taylor D, Barnes T, Young A. The Maudsley prescribing guidelines in psychiatry. 13th ed. Hoboken, NJ, USA: Wiley-Blackwell; 2018"},{"key":"142_CR8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2648.2008.04906.x","volume":"65","author":"TV McCann","year":"2009","unstructured":"McCann TV, Clark E, Lu S. Subjective side effects of antipsychotics and medication adherence in people with schizophrenia. J Adv Nurs. 2009;65:534\u201343.","journal-title":"J Adv Nurs"},{"key":"142_CR9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.31887\/DCNS.2014.16.4\/jpouget","volume":"16","author":"JG Pouget","year":"2014","unstructured":"Pouget JG, Shams TA, Tiwari AK, M\u00fcller DJ. Pharmacogenetics and outcome with antipsychotic drugs. Dialogues Clin Neurosci. 2014;16:555\u201366.","journal-title":"Dialogues Clin Neurosci"},{"key":"142_CR10","doi-asserted-by":"publisher","unstructured":"Corponi F, Fabbri C, Serretti A. Chapter Twelve - Pharmacogenetics in Psychiatry. In:\u00a0 Br\u00f8sen K, Damkie P, editors. Advances in Pharmacology. Academic Press. 2018.\u00a0Vol. 83. p. 297\u2013331. https:\/\/doi.org\/10.1016\/bs.apha.2018.03.003.","DOI":"10.1016\/bs.apha.2018.03.003"},{"key":"142_CR11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/11318070-000000000-00000","volume":"48","author":"S-F Zhou","year":"2009","unstructured":"Zhou S-F. Polymorphism of human cytochrome P450 2D6 and its clinical significance part II. Clin Pharmacokinet. 2009;48:761\u2013804.","journal-title":"Clin Pharmacokinet."},{"key":"142_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/tpj.2012.45","volume":"13","author":"S Sim","year":"2012","unstructured":"Sim S, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenom J. 2012;13:1\u201311.","journal-title":"Pharmacogenom J."},{"key":"142_CR13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/01.jcp.0000177546.34799.af","volume":"25","author":"J de Leon","year":"2005","unstructured":"de Leon J, Susce MT, Pan R-M, Koch WH, Wedlund PJ. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol. 2005;25:448\u201356.","journal-title":"J Clin Psychopharmacol"},{"key":"142_CR14","doi-asserted-by":"crossref","unstructured":"Haertter S. Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6. Drug Metabol Drug Interact. 2013;28:209\u201316.","DOI":"10.1515\/dmdi-2013-0032"},{"key":"142_CR15","doi-asserted-by":"crossref","unstructured":"Hamilton SP. The promise of psychiatric pharmacogenomics. Biol Psychiatry. 2015;77:29\u201335.","DOI":"10.1016\/j.biopsych.2014.09.009"},{"key":"142_CR16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/17512433.2016.1112737","volume":"9","author":"J de Leon","year":"2016","unstructured":"de Leon J, Spina E. What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy? Expert Rev Clin Pharm. 2016;9:351\u20134.","journal-title":"Expert Rev Clin Pharm"},{"key":"142_CR17","doi-asserted-by":"crossref","unstructured":"Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, et al. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol Assess. 2010;14:1\u2013157.","DOI":"10.3310\/hta14030"},{"key":"142_CR18","doi-asserted-by":"publisher","unstructured":"Walden LM, Brandl EJ, Tiwari AK, Cheema S, Freeman N, Braganza N, et al. Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication. Psychiatry Res. 2019;279:111\u2013115. https:\/\/doi.org\/10.1016\/j.psychres.2018.02.055. Epub 9 Mar 2018.","DOI":"10.1016\/j.psychres.2018.02.055"},{"key":"142_CR19","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/0269881107078281","volume":"21","author":"C Bushe","year":"2007","unstructured":"Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol. 2007;21:768\u201373.","journal-title":"J Psychopharmacol."},{"issue":"2 Suppl","key":"142_CR20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0269881107088436","volume":"22","author":"C Bushe","year":"2008","unstructured":"Bushe C, Yeomans D, Floyd T, Smith SM. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol. 2008;22(2 Suppl):56\u201362.","journal-title":"J Psychopharmacol."},{"key":"142_CR21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0269881114562090","volume":"29","author":"SL Young","year":"2015","unstructured":"Young SL, Taylor M, Lawrie SM. \u201cFirst do no harm.\u201d A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol. 2015;29:353\u201362.","journal-title":"J Psychopharmacol."},{"key":"142_CR22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte J, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273\u201388.","journal-title":"J Clin Endocrinol Metab"},{"key":"142_CR23","first-page":"575","volume":"169","author":"O Serri","year":"2003","unstructured":"Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ. 2003;169:575\u201381.","journal-title":"CMAJ."},{"key":"142_CR24","unstructured":"D\u2019Sylva C, Khan T, van uum S, Fraser, L. Osteoporotic fractures in patients with untreated hyperprolactinemia vs. those taking dopamine agonists: A systematic review and meta-analysis. Neuro Endocrinol Lett. 2015;36:745\u201349."},{"key":"142_CR25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hup.1116","volume":"25","author":"S Madhusoodanan","year":"2010","unstructured":"Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics-a review. Hum Psychopharmacol. 2010;25:281\u201397.","journal-title":"Hum Psychopharmacol."},{"key":"142_CR26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","volume":"28(Suppl 2)","author":"BJ Kinon","year":"2003","unstructured":"Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28(Suppl 2):55\u201368.","journal-title":"Psychoneuroendocrinology"},{"key":"142_CR27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/hup.811","volume":"21","author":"KI Melkersson","year":"2006","unstructured":"Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol. 2006;21:529\u201332.","journal-title":"Hum Psychopharmacol."},{"key":"142_CR28","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s002130051171","volume":"147","author":"MG Scordo","year":"1999","unstructured":"Scordo MG, Spina E, Facciol\u00e0 G, Avenoso A, Johansson I, Dahl ML. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology. 1999;147:300\u20135.","journal-title":"Psychopharmacology"},{"key":"142_CR29","doi-asserted-by":"publisher","unstructured":"Fleeman N, Dundar Y, Dickson R, Jorgensen A, Pushpakom S, McLeod C, et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenom J. 2011;11:1\u201314. https:\/\/doi.org\/10.1038\/tpj.2010.73. Epub 28 Sep 2010.","DOI":"10.1038\/tpj.2010.73"},{"key":"142_CR30","doi-asserted-by":"publisher","unstructured":"Dodsworth T, Kim DD, Procyshyn RM, Ross CJ, Honer WG, Barr AM. A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents. Child Adolesc Psychiatry Mental Health. 2018;12. https:\/\/doi.org\/10.1186\/s13034-018-0243-2.","DOI":"10.1186\/s13034-018-0243-2"},{"key":"142_CR31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/joim.12317","volume":"277","author":"J Stingl","year":"2015","unstructured":"Stingl J, Viviani R. Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. J Intern Med. 2015;277:167\u201377.","journal-title":"J Intern Med"},{"key":"142_CR32","doi-asserted-by":"publisher","unstructured":"Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, M\u00fcller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102:37\u201344. https:\/\/doi.org\/10.1002\/cpt.597 Epub 13 Feb 2017.","DOI":"10.1002\/cpt.597"},{"key":"142_CR33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","volume":"53","author":"L Bertilsson","year":"2002","unstructured":"Bertilsson L, Dahl ML, Dal\u00e9n P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53:111\u201322.","journal-title":"Br J Clin Pharmacol"},{"key":"142_CR34","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. NY: Academic Press; 1969."},{"key":"142_CR35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ Br Med J. 2003;327:557\u201360.","journal-title":"BMJ Br Med J"},{"key":"142_CR36","doi-asserted-by":"crossref","unstructured":"Sterne JA, Egger M, Moher D. Cochrane handbook: general methods for cochrane reviews: Ch 10: addressing reporting biases. In: Cochrane handbook for systematic reviews of interventions. 2011; p. 297\u2013334.","DOI":"10.1002\/9780470712184.ch10"},{"key":"142_CR37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/hup.2420","volume":"29","author":"T Cabaleiro","year":"2014","unstructured":"Cabaleiro T, Ochoa D, L\u00f3pez-Rodr\u00edguez R, Rom\u00e1n M, Novalbos J, Ayuso C, et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. Hum Psychopharmacol. 2014;29:459\u201369.","journal-title":"Hum Psychopharmacol."},{"key":"142_CR38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/YIC.0000000000000047","volume":"30","author":"T Cabaleiro","year":"2015","unstructured":"Cabaleiro T, L\u00f3pez-Rodr\u00edguez R, Rom\u00e1n M, Ochoa D, Novalbos J, Borobia A, et al. Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects. Int Clin Psychopharmacol. 2015;30:82\u20138.","journal-title":"Int Clin Psychopharmacol"},{"key":"142_CR39","doi-asserted-by":"publisher","unstructured":"Choong E, Polari A, Kamdem RH, Gervasoni N, Spisla C, Jaquenoud Sirot, et al. Prolactin levels: sex differences in the effects of risperidone, 9-hydroxyrisperidone levels, CYP2D6 and ABCB1 variants. J Clin Psychopharmacol. 2013;33:289\u201398. https:\/\/doi.org\/10.1097\/JCP.0b013e31828f62cd.","DOI":"10.1097\/JCP.0b013e31828f62cd"},{"key":"142_CR40","doi-asserted-by":"crossref","unstructured":"Schoretsanitis G, de Leon J, Diaz FJ. Prolactin levels: sex differences in the effects of risperidone, 9-hydroxyrisperidone levels, CYP2D6 and ABCB1 variants. Pharmacogenomics. 2018;19:815\u201323.\u00a0","DOI":"10.2217\/pgs-2018-0053"},{"key":"142_CR41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/hup.2308","volume":"28","author":"T Cabaleiro","year":"2013","unstructured":"Cabaleiro T, L\u00f3pez-Rodr\u00edguez R, Ochoa D, Rom\u00e1n M, Novalbos J, Abad-Santos F. Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Hum Psychopharmacol. 2013;28:205\u201314.","journal-title":"Hum Psychopharmacol."},{"key":"142_CR42","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40262-015-0289-8","volume":"54","author":"F Vandenberghe","year":"2015","unstructured":"Vandenberghe F, Guidi M, Choong E, von Gunten A, Conus P, Csajka C, et al. Genetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort. Clin Pharmacokinet. 2015;54:1259\u201372.","journal-title":"Clin Pharmacokinet."},{"key":"142_CR43","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/JCP.0b013e3181ee84c7","volume":"30","author":"J Novalbos","year":"2010","unstructured":"Novalbos J, L\u00f3pez-Rodr\u00edguez R, Rom\u00e1n M, Gallego-Sand\u00edn S, Ochoa D, Abad-Santos F. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. J Clin Psychopharmacol. 2010;30:504\u201311.","journal-title":"J Clin Psychopharmacol"},{"key":"142_CR44","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/FPC.0b013e32801a3c10","volume":"17","author":"V Ozdemir","year":"2007","unstructured":"Ozdemir V, Bertilsson L, Miura J, Carpenter E, Reist C, Harper P, et al. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet Genom. 2007;17:339\u201347.","journal-title":"Pharmacogenet Genom."},{"key":"142_CR45","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/FPC.0b013e3283647c33","volume":"23","author":"Y Roke","year":"2013","unstructured":"Roke Y, van Harten PN, Franke B, Galesloot TE, Boot AM, Buitelaar JK. The effect of the Taq1A variant in the dopamine D2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys. Pharmacogenet Genom. 2013;23:487\u201393.","journal-title":"Pharmacogenet Genom."},{"key":"142_CR46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JCP.0b013e31802e68d5","volume":"27","author":"PW Troost","year":"2007","unstructured":"Troost PW, Lahuis BE, Hermans MH, Buitelaar JK, van Engeland H, Scahill L, et al. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol. 2007;27:52\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"142_CR47","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/dmcn.12470","volume":"56","author":"I Youngster","year":"2014","unstructured":"Youngster I, Zachor DA, Gabis LV, Bar-Chaim A, Benveniste-Levkovitz P, Britzi M, et al. CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study. Dev Med Child Neurol. 2014;56:990\u20134.","journal-title":"Dev Med Child Neurol"},{"key":"142_CR48","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0269881107077357","volume":"21","author":"L Wang","year":"2007","unstructured":"Wang L, Yu L, Zhang AP, Fang C, Du J, Gu NF, et al. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J Psychopharmacol. 2007;21:837\u201342.","journal-title":"J Psychopharmacol."},{"key":"142_CR49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0920-9964(00)00178-X","volume":"52","author":"N Yasui-Furukori","year":"2001","unstructured":"Yasui-Furukori N, Kondo T, Suzuki A, Mihara K, Tokinaga N, Inoue Y, et al. Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol. Schizophr Res 2001;52:139\u201342.","journal-title":"Schizophr Res"},{"key":"142_CR50","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1089\/cap.2015.0094","volume":"25","author":"A dos Santos J\u00fanior","year":"2015","unstructured":"dos Santos J\u00fanior A, Henriques TB, de Mello MP, APF Neto, Paes LA, Torre OH Della, et al. Hyperprolactinemia in children and adolescents with use of risperidone: clinical and molecular genetics aspects. J Child Adolesc Psychopharmacol. 2015;25:738\u201348.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"142_CR51","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s10517-016-3250-4","volume":"160","author":"SA Ivanova","year":"2016","unstructured":"Ivanova SA, Filipenko ML, Vyalova NM, Voronina EN, Pozhidaev IV, Osmanova DZ, et al. CYP1A2 and CYP2D6 gene polymorphisms in schizophrenic patients with neuroleptic drug-induced side effects. Bull Exp Biol Med. 2016;160:687\u201390.","journal-title":"Bull Exp Biol Med"},{"key":"142_CR52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JCP.0000000000000474","volume":"36","author":"C Sukasem","year":"2016","unstructured":"Sukasem C, Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Chamnanphon M, et al. Impact of pharmacogenetic markers of CYP2D6 and DRD2 on prolactin response in risperidone-treated Thai children and adolescents with autism spectrum disorders. J Clin Psychopharmacol. 2016;36:1.","journal-title":"J Clin Psychopharmacol"},{"key":"142_CR53","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/10937400903158342","volume":"12","author":"P Neafsey","year":"2009","unstructured":"Neafsey P, Ginsberg G, Hattis D, Sonawane B. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. J Toxicol Environ Heal Part B. 2009;12:334\u201361.","journal-title":"J Toxicol Environ Heal Part B."},{"key":"142_CR54","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1517\/17425255.2014.964204","volume":"10","author":"A LLerena","year":"2014","unstructured":"LLerena A, Naranjo MEG, Rodrigues-Soares F, Penas-LLed\u00f3 EM, Fari\u00f1as H, Tarazona-Santos E. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol. 2014;10:1569\u201383.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"142_CR55","doi-asserted-by":"publisher","unstructured":"Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102:688\u2013700. https:\/\/doi.org\/10.1002\/cpt.690. Epub 26 May 2017.","DOI":"10.1002\/cpt.690"},{"key":"142_CR56","doi-asserted-by":"publisher","unstructured":"Staley LA, Ebbert MTW, Parker S, Bailey M, Alzheimer\u2019s Disease Neuroimaging Initiative, Ridge PG. et al. Genome-wide association study of prolactin levels in blood plasma and cerebrospinal fluid. BMC Genom. 2016;17. https:\/\/doi.org\/10.1186\/s12864-016-2785-0.","DOI":"10.1186\/s12864-016-2785-0"},{"key":"142_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psyneuen.2016.06.002","volume":"72","author":"I Miura","year":"2016","unstructured":"Miura I, Zhang J-P, Hagi K, Lencz T, Kane JM, Yabe H, et al. Variants in the DRD2 locus and antipsychotic-related prolactin levels: a meta-analysis. Psychoneuroendocrinology. 2016;72:1\u201310.","journal-title":"Psychoneuroendocrinology."},{"key":"142_CR58","doi-asserted-by":"publisher","unstructured":"Bakken GV, Molden E, Hermann M. Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients. Ther Drug Monit.\u00a02015;37:256\u201361. https:\/\/doi.org\/10.1097\/FTD.0000000000000135.","DOI":"10.1097\/FTD.0000000000000135"},{"key":"142_CR59","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","volume":"37","author":"JT Callaghan","year":"1999","unstructured":"Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177\u201393.","journal-title":"Clin Pharmacokinet."},{"key":"142_CR60","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/bcpt.12093","volume":"113","author":"L Herbild","year":"2013","unstructured":"Herbild L, Andersen SE, Werge T, Rasmussen HB, J\u00fcrgens G. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs? Basic Clin Pharm Toxicol. 2013;113:266\u201372.","journal-title":"Basic Clin Pharm Toxicol"},{"key":"142_CR61","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","volume":"5","author":"M Ingelman-Sundberg","year":"2005","unstructured":"Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6\u201313.","journal-title":"Pharmacogenomics J."},{"key":"142_CR62","unstructured":"Otsuka America Pharmaceutical. ABILIFY: highlights of prescribing information. Tokyo, Japan: Otsuka America Pharmaceutical; 2014."},{"key":"142_CR63","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","volume":"98","author":"JK Hicks","year":"2015","unstructured":"Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharm Ther. 2015;98:127\u201334.","journal-title":"Clin Pharm Ther"},{"key":"142_CR64","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/070674371405900203","volume":"59","author":"EJ Brandl","year":"2014","unstructured":"Brandl EJ, Kennedy JL, M\u00fcller DJ. Pharmacogenetics of antipsychotics. Can J Psychiatry. 2014;59:76\u201388.","journal-title":"Can J Psychiatry"},{"key":"142_CR65","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.psychres.2015.07.032","volume":"229","author":"LM Walden","year":"2015","unstructured":"Walden LM, Brandl EJ, Changasi A, Sturgess JE, Soibel A, Notario JFD, et al. Physicians\u2019 opinions following pharmacogenetic testing for psychotropic medication. Psychiatry Res. 2015;229:913\u20138.","journal-title":"Psychiatry Res."},{"key":"142_CR66","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","volume":"92","author":"M Whirl-Carrillo","year":"2012","unstructured":"Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Therapeutics. 2012;92:414\u20137.","journal-title":"Clin Pharmacol Therapeutics"},{"key":"142_CR67","doi-asserted-by":"publisher","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097. Epub 21 Jul 2009.","DOI":"10.1371\/journal.pmed.1000097"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0142-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0142-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0142-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:00:17Z","timestamp":1684616417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-019-0142-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["142"],"URL":"https:\/\/doi.org\/10.1038\/s41397-019-0142-9","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]},"assertion":[{"value":"30 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}